SG11201906249PA - Methods, compositions, and kits for treatment of cancer - Google Patents

Abstract

FIGB-701 Gmup 5 No surviving animals in single agent chemo arms (Gemcitabine. Paclitaxel at high, mid, low dose) 100 90 80 70 60 /2 50 4° k 30 20 10 10 20 30 Gmupr Prolonged GmupS surviva l in animals treated Group 9 with B-701 Combinations (B-701 Gemcitabine or Paclitaxel at high or mid dose) Gf011p 10 W O 20 18/ 145 120 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT omit VIII °nolo VIII mum Hollow° (10) International Publication Number WO 2018/145120 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/017121 (22) International Filing Date: 06 February 2018 (06.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/455,494 06 February 2017 (06.02.2017) US 62/511,869 26 May 2017 (26.05.2017) US (71) Applicant: BIOCLIN THERAPEUTICS, INC. [US/US]; 1040 Davis Street, Suite 202, San Leandro, California 94577 (US). (72) Inventor: HOLASH, Jocelyn; 321 Charming Way, Alame- da, California 94502 (US). (74) Agent: MORRIS, Patrick; Perkins Coie LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) (54) Title: METHODS, COMPOSITIONS, AND KITS FOR TREATMENT OF CANCER (57) : Provided herein are the use of FGFR3 inhibitors and taxanes to treat solid and hematologic cancers, as well as composi- tions and kits comprising an FGFR3 inhibitor and a taxane. Group 1 vehicle (iv, biwk x4) i r Group 2: pacirlaxel (5 mg/kg, iv, qwk x 4) .16 Group 3: padttaxel (10 mg/kg, Iv, qwk x2), pacIllaxal (40 mghig, Iv, qwk x2 (slad on day 15)) Group 4: padilaxel (20 mg/kg, iv, qwk x4) Ai . Group 5. gemcilabile (60 mg/kg, ip, q3d x 4) Group 6 BM2 (30 mg/kg, Iv, blwk x 4) Group 7 BM2 (30 mg/kg, iv, biwk, x4), gemoilabine (60 mg/kg, ip, q3d x 4) Group B. BM2 (30 mg/kg, Iv, Mak, x4), paella/cal (5 Mg/kg, Iv, qwk x4) Group 9: BM2 (30 mg/kg, iv, biwk, x4), packlaxel (10 mg/kg, iv, qwk x 2), paclilaxel (40 mg/kg, iv, qwk 52 (start on day 15)) Group 10: BM2 (30 mg/kg, iv, biwk, x4), pacgaxel (20 mg/kg, kr, qwk x 4) [Continued on next page] WO 2018/145120 Al MIDEDIM011111 1111E111E3010111111111111111111111011111111111111111 Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))